These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17033232)

  • 1. [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression].
    Shiiki S; Sonoo H; Seki M; Nomura T; Hironou M; Ookubo S; Udagawa K; Yamamoto Y; Nakashima K; Ikeda M; Tanaka K; Kurebayashi J
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1431-5. PubMed ID: 17033232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer].
    Wang T; Jiang ZF; Song ST; Zhang SH; Shen G; Yu JX
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):379-81. PubMed ID: 15312353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [More effective positioning of capecitabine for advanced and metastatic breast cancer].
    Tsuyuki S; Kawaguchisakita N; Tsubota Y; Ukikusa M; Kohno Y
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):649-53. PubMed ID: 20414020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
    Osako T; Ito Y; Ushijima M; Takahashi S; Tokudome N; Sugihara T; Iwase T; Matsuura M; Hatake K
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):865-71. PubMed ID: 18670777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
    Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer.
    Amari M; Ishida T; Takeda M; Ohuchi N
    Jpn J Clin Oncol; 2010 Mar; 40(3):188-93. PubMed ID: 19887522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
    Pierga JY; Fumoleau P; Brewer Y; Zelek L; Martin D; Turpin FL; Goudier MJ; Gil-Delgado M; Baticle JL; Namer M; Chollet P; Sutherland W; Barats JC;
    Breast Cancer Res Treat; 2004 Nov; 88(2):117-29. PubMed ID: 15564795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
    Hess D; Koberle D; Thurlimann B; Pagani O; Schonenberger A; Mattmann S; Rochlitz C; Rauch D; Schuller JC; Ballabeni P; Ribi K;
    Oncology; 2007; 73(3-4):228-37. PubMed ID: 18424887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
    Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
    Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R; Okumura Y; Arima N
    Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?
    Yap YS; Kendall A; Walsh G; Banerji U; Johnston SR; Smith IE; O'Brien M
    Breast; 2007 Aug; 16(4):420-4. PubMed ID: 17379519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot phase II study of capecitabine in advanced or recurrent breast cancer.
    Saeki T; Kimura T; Toi M; Taguchi T
    Breast Cancer; 2006; 13(1):49-57. PubMed ID: 16518062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
    Akahane T; Chiba T; Yano H; Hashimoto Y
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):435-8. PubMed ID: 17353638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome.
    Sezgin C; Kurt E; Evrensel T; Ozdemir N; Manavoglu O; Goker E
    South Med J; 2007 Jan; 100(1):27-32. PubMed ID: 17269522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
    Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
    Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.